Drug-Eluting Vascular Stent System
Restenosis following nitinol stenting peaks at about 12 months in the SFA.
SUSTEND™ Drug-Delivery Technology
The Eluvia™ Stent, with Sustend™ drug-delivery technology, is designed to deliver paclitaxel when restenosis is most likely to occur.
Polymer-based technology with proven biocompatibility1
- Implanted in more than 10 million vessels since 2007
- More than 20,000 patients studied in clinical trials